Molecularly targeted therapies in non-small-cell lung cancer annual update 2014

Daniel Morgensztern; Meghan J. Campo; Suzanne E. Dahlberg; Robert C. Doebele; Edward Garon; David E. Gerber; Sarah B. Goldberg; Peter S. Hammerman; Rebecca S. Heist; Thomas Hensing; Leora Horn; Suresh S. Ramalingam; Charles M. Rudin; Ravi Salgia; Lecia V. Sequist; Alice T. Shaw; George R. Simon; Neeta Somaiah; David R. Spigel; John Wrangle; David Johnson; Roy S. Herbst; Paul Bunn; Ramaswamy Govindan

doi:10.1097/JTO.0000000000000405

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014

Daniel Morgensztern, Meghan J. Campo, Suzanne E. Dahlberg, Robert C. Doebele, Edward Garon, David E. Gerber, Sarah B. Goldberg, Peter S. Hammerman, Rebecca S. Heist, Thomas Hensing, Leora Horn, Suresh S. Ramalingam, Charles M. Rudin, Ravi Salgia, Lecia V. Sequist, Alice T. Shaw, George R. Simon, Neeta Somaiah, David R. Spigel, John WrangleDavid Johnson, Roy S. Herbst, Paul Bunn, Ramaswamy Govindan

Research output: Contribution to journal › Article › peer-review

117 Scopus citations

Abstract

There have been significant advances in the understanding of the biology and treatment of non-small-cell lung cancer (NSCLC) during the past few years. A number of molecularly targeted agents are in the clinic or in development for patients with advanced NSCLC. We are beginning to understand the mechanisms of acquired resistance after exposure to tyrosine kinase inhibitors in patients with oncogene addicted NSCLC. The advent of next-generation sequencing has enabled to study comprehensively genomic alterations in lung cancer. Finally, early results from immune checkpoint inhibitors are very encouraging. This review summarizes recent advances in the area of cancer genomics, targeted therapies, and immunotherapy.

Original language	English (US)
Pages (from-to)	S1-S63
Journal	Journal of Thoracic Oncology
Volume	10
Issue number	1
DOIs	https://doi.org/10.1097/JTO.0000000000000405
State	Published - Jan 13 2015

Keywords

Immunotherapy
Non-small-cell lung cancer
Targeted therapies

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine

Access to Document

10.1097/JTO.0000000000000405

Cite this

Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T., Horn, L., Ramalingam, S. S., Rudin, C. M., Salgia, R., Sequist, L. V., Shaw, A. T., Simon, G. R., Somaiah, N., Spigel, D. R., ... Govindan, R. (2015). Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. Journal of Thoracic Oncology, 10(1), S1-S63. https://doi.org/10.1097/JTO.0000000000000405

Morgensztern, D, Campo, MJ, Dahlberg, SE, Doebele, RC, Garon, E, Gerber, DE, Goldberg, SB, Hammerman, PS, Heist, RS, Hensing, T, Horn, L, Ramalingam, SS, Rudin, CM, Salgia, R, Sequist, LV, Shaw, AT, Simon, GR, Somaiah, N, Spigel, DR, Wrangle, J, Johnson, D, Herbst, RS, Bunn, P & Govindan, R 2015, 'Molecularly targeted therapies in non-small-cell lung cancer annual update 2014', Journal of Thoracic Oncology, vol. 10, no. 1, pp. S1-S63. https://doi.org/10.1097/JTO.0000000000000405

@article{a1856ec0425f4676aa3060e8f754b4ff,

title = "Molecularly targeted therapies in non-small-cell lung cancer annual update 2014",

abstract = "There have been significant advances in the understanding of the biology and treatment of non-small-cell lung cancer (NSCLC) during the past few years. A number of molecularly targeted agents are in the clinic or in development for patients with advanced NSCLC. We are beginning to understand the mechanisms of acquired resistance after exposure to tyrosine kinase inhibitors in patients with oncogene addicted NSCLC. The advent of next-generation sequencing has enabled to study comprehensively genomic alterations in lung cancer. Finally, early results from immune checkpoint inhibitors are very encouraging. This review summarizes recent advances in the area of cancer genomics, targeted therapies, and immunotherapy.",

keywords = "Immunotherapy, Non-small-cell lung cancer, Targeted therapies",

author = "Daniel Morgensztern and Campo, {Meghan J.} and Dahlberg, {Suzanne E.} and Doebele, {Robert C.} and Edward Garon and Gerber, {David E.} and Goldberg, {Sarah B.} and Hammerman, {Peter S.} and Heist, {Rebecca S.} and Thomas Hensing and Leora Horn and Ramalingam, {Suresh S.} and Rudin, {Charles M.} and Ravi Salgia and Sequist, {Lecia V.} and Shaw, {Alice T.} and Simon, {George R.} and Neeta Somaiah and Spigel, {David R.} and John Wrangle and David Johnson and Herbst, {Roy S.} and Paul Bunn and Ramaswamy Govindan",

note = "Publisher Copyright: Copyright {\textcopyright} 2014 by the International Association for the Study of Lung Cancer.",

year = "2015",

month = jan,

day = "13",

doi = "10.1097/JTO.0000000000000405",

language = "English (US)",

volume = "10",

pages = "S1--S63",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "International Association for the Study of Lung Cancer",

number = "1",

}

TY - JOUR

T1 - Molecularly targeted therapies in non-small-cell lung cancer annual update 2014

AU - Morgensztern, Daniel

AU - Campo, Meghan J.

AU - Dahlberg, Suzanne E.

AU - Doebele, Robert C.

AU - Garon, Edward

AU - Gerber, David E.

AU - Goldberg, Sarah B.

AU - Hammerman, Peter S.

AU - Heist, Rebecca S.

AU - Hensing, Thomas

AU - Horn, Leora

AU - Ramalingam, Suresh S.

AU - Rudin, Charles M.

AU - Salgia, Ravi

AU - Sequist, Lecia V.

AU - Shaw, Alice T.

AU - Simon, George R.

AU - Somaiah, Neeta

AU - Spigel, David R.

AU - Wrangle, John

AU - Johnson, David

AU - Herbst, Roy S.

AU - Bunn, Paul

AU - Govindan, Ramaswamy

PY - 2015/1/13

Y1 - 2015/1/13

N2 - There have been significant advances in the understanding of the biology and treatment of non-small-cell lung cancer (NSCLC) during the past few years. A number of molecularly targeted agents are in the clinic or in development for patients with advanced NSCLC. We are beginning to understand the mechanisms of acquired resistance after exposure to tyrosine kinase inhibitors in patients with oncogene addicted NSCLC. The advent of next-generation sequencing has enabled to study comprehensively genomic alterations in lung cancer. Finally, early results from immune checkpoint inhibitors are very encouraging. This review summarizes recent advances in the area of cancer genomics, targeted therapies, and immunotherapy.

AB - There have been significant advances in the understanding of the biology and treatment of non-small-cell lung cancer (NSCLC) during the past few years. A number of molecularly targeted agents are in the clinic or in development for patients with advanced NSCLC. We are beginning to understand the mechanisms of acquired resistance after exposure to tyrosine kinase inhibitors in patients with oncogene addicted NSCLC. The advent of next-generation sequencing has enabled to study comprehensively genomic alterations in lung cancer. Finally, early results from immune checkpoint inhibitors are very encouraging. This review summarizes recent advances in the area of cancer genomics, targeted therapies, and immunotherapy.

KW - Immunotherapy

KW - Non-small-cell lung cancer

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=84920740857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920740857&partnerID=8YFLogxK

U2 - 10.1097/JTO.0000000000000405

DO - 10.1097/JTO.0000000000000405

M3 - Article

C2 - 25535693

AN - SCOPUS:84920740857

SN - 1556-0864

VL - 10

SP - S1-S63

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 1

ER -

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this